▎药明康德内容团队编辑日前，辉瑞（Pfizer）宣布美国FDA已批准其呼吸道合胞病毒（RSV）疫苗Abrysvo（RSVpreF），用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病（LRTD）。此前，该疫苗已获批用于60岁及以上的成人群体。根 ...

｜ 2024年10月24日 星期四 ｜ NO.1 诺泰生物及实际控制人之一被证监会立案 ...

Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

智通财经获悉，美国食品药品监督管理局(FDA)已批准辉瑞公司(PFE.US)的呼吸道合胞病毒(RSV)疫苗Abrysvo用于18至59岁下呼吸道疾病风险增加的人群。这些疾病包括肥胖、糖尿病、慢性阻塞性肺病、心力衰竭、慢性肾病和哮喘。扩大批准是基于3期 ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.